Skip Navigation

European Heart Journal 1988 9(12):1324-1331;
Copyright © 1988 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by PIRELLI, S.
Right arrow Articles by CAMPOLO, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PIRELLI, S.
Right arrow Articles by CAMPOLO, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1988 The European Society of Cardiology

Dipyridamole–thallium 201 scintigraphy in the early post-infarction period: (Safety and accuracy in predicting the extent of coronary disease and future recurrence of angina in patients suffering from their first mycocardial infarction)

S. PIRELLI, E. INGLESE, M. SUPPA, E. CORRADA and L. CAMPOLO

Centro A. De Gasperis, Ente Ospedaliero Niguarda – Ca' Granda Piazza Ospedale Maggiore 3, 20162 Milano, Italy

Received 23 November 1987; revised 17 June 1988; .

Abstract

To evaluate the safety and usefulness of myocardial thallium-201 scintigraphy after intravenous dipyridamole during the early post-infarction period, 35 patients under 60 years of age and with recent first transmural uncomplicated myocardial infarction (27 inferior, 8 anterior) were examined between the 5th and 13th day of hospilization. Although four patients experienced angina and transient ischemic ST depression during the test, there were no serious complications. Patients were followed for a mean period of 11.4±6.3 months after hospital dicharge. None of the patients experienced recurrent infarction and there were no cardiac deaths. In 11 patients there were reversible prefusion defects in areas different from those of myocardial infarction. Of these patients, seven (one with infarct vessel stenosis only and six with multivessel coronary disease) developed angina during the follow-up: five underwent coronary surgery because of severe angina refractory to full medical theraphy. Out of the 24 patients without reversible perfusion defects, only two (with multivessel coronary disease) showed typical angina sysmptoms. The presence of redistribution on thallium scans was significantly more frequent in patients who developed a recurrence of angina over a period of 11.4±6.3 months of follow-up (p<0.0005). Thus dipyridamole–thallium 201 scintigraphy is a safe, non-invasive stress test which may be used early following uncomplicated myocardial infarction in order to indentify patients at risk for the recurrence of angina.

Key Words: Risk Stratification (after myocardial infarction), • thallium perfusion defects, • dipyridamole-thallium 201 scintigraphy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
J. Hung, M. Moshiri, G. N Groom, A. A Van der Schaaf, R. W Parsons, and M. E Hands
Dipyridamole thallium-201 scintigraphy for early risk stratification of patients after uncomplicated myocardial infarction
Heart, October 1, 1997; 78(4): 346 - 352.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
M.G. Niemeye, E.E. Van der Wall, E.K.J. Pauwels, P.R.M. van Dijkman, J.A.K. Blokland, A. de Roos, and A.V.G. Bruschke
Assessment of Acute Myocardial Infarction by Nuclear Imaging Techniques
Angiology, September 1, 1992; 43(9): 720 - 733.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.